News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Chemotherapy reduces testicular cancer relapse and side effects
Giving men with stage 2 testicular cancer a single dose of carboplatin alongside radiotherapy could improve treatment effectiveness and reduce the risk of long-term side-effects, an ICR study reports.
ICR researchers in new international trial for neuroblastoma
New 'BEACON' trial led by ICR scientists aims to tackle treatment-resistant form of childhood cancer neuroblastoma.
Experimental breast cancer drugs could treat lung cancer too
Scientists discover that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer.
Trial compares new drug combinations for breast cancer
A combination of two hormone therapy drugs does not provide significant clinical benefit over single-drug treatments, according to a trial.
Science Writer of the Year 2013
The ICR’s annual Mel Greaves Science Writing Prize – named in honour of the ICR Professor of Cell Biology and popular science author Professor Mel Greaves – aims to encourage imaginative writing about science that is engaging and understandable not only for fellow scientists but also for the wider public.
Luke Johnson, leading entrepreneur, takes the helm at the ICR
This week, Luke Johnson, one of the UK’s most successful entrepreneurs and former Chairman of Channel 4, joins the ICR as Chairman.
Cancer Research Technology, The Institute of Cancer Research and Merck Serono sign licensing deal on molecules that block the WNT signalling pathway
The Institute of Cancer Research, London, Cancer Research Technology, and Merck Serono have signed a licensing deal today extending an alliance to discover and develop anticancer drugs that block the WNT signalling pathway.
Men with incurable prostate cancer living twice as long as decade ago
Patients with advanced prostate cancer treated with the latest therapies are living twice as long as a decade ago, a new ICR analysis reveals.
Video: Men with advanced prostate cancer are living longer
Patients with advanced prostate cancer treated with the latest therapies are living on average for more than twice as long as a decade ago. Study leader Professor Johann de Bono told us why:
Study shows benefit of thalidomide in treatment of myeloma
The controversial drug thalidomide could play an important role in treatment of myeloma by eradicating the final, residual traces of cancerous cells in patients.
Losing weight could lower women's risk of breast cancer
Losing weight could help women lower their risk of developing breast cancer by reducing levels of key sex hormones, a new study reports.
New drug that targets DNA packaging passes phase I trial
A new potential cancer drug is due to move into trials to test its effectiveness in patients with cancer, after a successful phase I trial led by Institute of Cancer Research, London researchers at the Royal Marsden NHS Foundation Trust.
